home / stock / cfrx / cfrx news

CFRX News and Press, ContraFect Corporation From 12/13/22

Stock Information
Company Name: ContraFect Corporation
Stock Symbol: CFRX
Market: NASDAQ
Website: contrafect.com
Menu
CFRX CFRX Quote CFRX Short CFRX News CFRX Articles CFRX Message Board
Get CFRX Alerts

News, Short Squeeze, Breakout and More Instantly...
CFRX - ContraFect to purchase ~$7M of shares

Clinical-stage biotechnology company ContraFect ( NASDAQ: CFRX ) is set to purchase ~$7M of its common stock. The company has entered into a securities purchase agreement with a single institutional investor for the purchase. CFRX has agreed to issue 4,350,000 shares and and ...
CFRX - ContraFect Announces Pricing of $7.0 Million Registered Direct Offering and Concurrent Private Placement

YONKERS, N.Y., Dec. 13, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX) , a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of ...

CFRX - 3 Hot Penny Stocks To Watch Under $1 Right Now

Looking For Cheap Stocks To Buy For Under $1? Check Out Penny Stocks It might seem evident that penny stocks include shares of companies trading for prices below $0.99. But according to the broader definition, the term includes other stocks that trade for less than $5. Whichever definition yo...

CFRX - ContraFect Announces ANSM Approval of Clinical Trial Application for Exebacase in Prosthetic Joint Infections

YONKERS, N.Y., Nov. 28, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX) , a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatme...
CFRX - Contrafect GAAP EPS of -$0.43 misses by $0.20

Contrafect press release ( NASDAQ: CFRX ): Q2 GAAP EPS of -$0.43 misses by $0.20 . As of September 30, 2022, ContraFect had cash, cash equivalents and marketable securities of $17.6 million. For further details see: Contrafect GAAP EPS of -$0.43 misses by $0....

CFRX - ContraFect Reports Third Quarter 2022 Financial Results and Provides Corporate Update

YONKERS, N.Y., Nov. 14, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX) , a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the tre...

CFRX - ContraFect Announces Multiple Publications Highlighting the Potential Utility of Lysins for the Treatment of Bone and Joint Infections

YONKERS, N.Y., Sept. 12, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX) , a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatm...
CFRX - ContraFect Announces Presentation of New Clinical Data From a Study Using Exebacase in the LysinDAIR Procedure on Patients With Chronic Knee Prosthetic Joint Infection

YONKERS, N.Y., Sept. 12, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX) , a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatm...

CFRX - Contrafect GAAP EPS of -$0.46 misses by $0.13

Contrafect press release ( NASDAQ: CFRX ): Q2 GAAP EPS of -$0.46 misses by $0.13 . As of June 30, 2022, ContraFect had cash, cash equivalents and marketable securities of $27.3 million. Shares +4% PM For further details see: Contrafect GAAP EPS of -$0...

CFRX - ContraFect Reports Second Quarter 2022 Financial Results and Provides Corporate Update

YONKERS, N.Y., Aug. 15, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX) , a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the tre...
Previous 10 Next 10